Heart defects similar to those alleged in several recent Zofran lawsuit claims may be significantly more likely to occur in children of mothers who were exposed to the anti-nausea medication in the womb than those who were not, according to research published at the end of last year.

A study published in a December 2014 issue of Reproductive Toxicity finds that these individuals are 62% more likely to experience cardiovascular problems, and are also at an increased risk of developing an atrial septal defect (ASD) or a ventricular septal defect (VSD). The results were obtained by a group of Swedish researchers from the National Board of Health and Welfare, who looked at data from 1,349 infants born to women who took Zofran early in pregnancies that occurred between 1998 and 2012. Given their findings, researchers concluded that the GlaxoSmithKline medication should not be prescribed to women with extreme nausea during pregnancy, a condition referred to as hyperemesis gravidarum (HG).

What some may not realize though is that Zofran is not approved by the U.S. Food and Drug Administration (FDA) as a treatment for women during pregnancy. Cleared on the U.S. market in 1991, the medication is strictly cleared to relieve nausea symptoms in patients undergoing chemotherapy or radiation, or another type of surgery. In response to a Toronto Star investigation published in the spring of 2014, GlaxoSmithKline admitted that the drug has not been proven effective in treating pregnant women, despite its frequent off-label prescription for this use.

January Case Study Lends Evidence to Zofran Heart Defects

This past January, a case study related to Zofran heart defects lent evidence to the medication’s potential for serious heart problems in children. The results were published in Pediatric Emergency Care and found fatalities that resulted in two individuals –one aged 10 and the other just 86 days old—who took the medication for gastroenteritis symptoms. Both developed heart rates that were faster than normal after being given Zofran, before they went unresponsive and later died. The infant was discovered later to have had congenital heart defects prior to his taking the drug.

According to court documents, a number of Zofran lawsuits that allege serious birth defects have been filed throughout the U.S.

Call a Zofran Lawyer to File a Case of Your Own.

Zofran lawyers at our Firm are standing by to answer any questions you have regarding the process of filing a claim against GlaxoSmithKline. Call us now at (877) 779-1414.

Published March 16, 2015 by